LAM Pharmaceutical Corporation (LAMP) And Ixora Bio Medical Announce The Launch Of Ixora's First Product 
10/19/2005 5:09:17 PM

LEWISTON, N.Y., Nov. 25 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that Ixora Bio Medical Company Inc., a licensee of LAM, is poised to commence marketing and commercial sales of "Ixora(TM) for Women", a non-prescription female sexual enhancement product Ixora has licensed from LAM.

John Easton, Chief Executive Officer of Ixora Bio Medical, stated, "The impending launch of 'Ixora(TM) for Women' represents a major milestone for us. It is the culmination of four years of extensive research and development, clinical studies and marketing research. 'Ixora(TM) for Women' is the first of several products addressing sexual dysfunction in both men and women based on LAM IPM Ionic Polymer Matrix platform that Ixora has licensed from LAM. It will be marketed and sold as a sophisticated, upscale sexual enhancement product, addressing the difficulties associated with female sexual function disorders. The Journal of the American Medical Association has stated that 43.0% of American women have faced at least one sexual function issue. These statistics are based on a national sampling of women ages 18-59."

Mr. Easton added, "In preparation for the launch, Ixora has assembled a group of first class professionals including a medical advisory board as well as branding, marketing and public relations teams. Ixora Bio Medical has established a network of sales outlets throughout North America for its 'Ixora(TM) for Women' and has contracted manufacturing to a leading New Jersey based FDA approved GMP manufacturing facility."

Joseph Slechta, President and Chief Executive Officer of LAM, remarked, "We are very pleased about our licensee's achievement. Ixora has had our total support throughout the commercialization stage. We will work with Ixora's marketing team to ensure the successful launch of its first product. LAM anticipates royalty revenues from 'Ixora(TM) for Women' to commence in the first half of 2004."

Mr. Slechta concluded, "The upcoming launch of 'Ixora(TM) for Women' is particularly timely. The subject of human sexuality has come to the forefront in recent years and we are proud that Ixora has the opportunity to make a major positive contribution to this field."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp.,, is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 14 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

About Ixora Bio Medical Company Inc.

Ixora Bio Medical Company is a biomedical company with headquarters in New York City. Ixora holds a world wide exclusive license from LAM for sexual dysfunction products based on LAM's patented proprietary IPM Ionic Polymer Matrix transdermal delivery platform. The Company's current focus is to develop and commercialize sexual enhancement products. More information about Ixora can be obtained by visiting

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

LAM Pharmaceutical, Corp.

CONTACT: investors/media, Stephanie Carrington of The Ruth Group,+1-646-536-7017, for LAM Pharmaceutical, Corp.